Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial

American Heart Journal

Volumn 164, Issue 6, 2012, Pages

  Lin, Gen Min ^a   Li, Yi Hwei ^b   Jaiteh, Lamin E S ^c   Han, Chih Lu ^d  

^a HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c Royal Victoria Teaching Hospital Gambia   (Gambia)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; PEXELIZUMAB;

CELL CULTURE; COMPLEMENT ACTIVATION; DOSE RESPONSE; HEART PROTECTION; HUMAN; IN VIVO STUDY; INFLAMMATION; INJURY SEVERITY; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; SINGLE-CHAIN ANTIBODIES;

EID: 84870299885     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.09.012     Document Type: Letter

References (8)

1. C. Martel, C.B. Granger, and M. Ghitescu Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial Am Heart J 164 2012 43 51
2. C.S. Rinder, H.M. Rinder, and B.R. Smith Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J Clin Invest 96 1995 1564 1572
3. J.C. Fitch, S. Rollins, and L. Matis Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass Circulation 100 1999 2499 2506
4. M. Roger, K. Hogåsen, and P.A. Holme The fluid-phase SC5b-9 terminal complement complex binds to the GPIIb/IIIa complex of thrombin-stimulated human blood platelets inhibiting platelet aggregation Platelet 6 1995 160 168
5. G.M. Lin, K.M. Chu, and C.L. Han Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors Int J Cardiol 146 2010 280 282
6. G.M. Lin, Y.H. Li, and S.H. Wen Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization Int J Cardiol 147 2011 340 341
7. G.M. Lin Pexelizumab, an anti-C5 complement antibody for primary coronary revascularization: a new insight from old versions Cardiovasc Hematol Disord Drug Targets 11 2011 97 101
8. Y. Sawa, H. Ichikawa, and K. Kagisaki Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium J Thorac Cardiovasc Surg 116 1998 511 517